-

05:28:03 PM

ADCT Stock News

ADCT - Adc Therapeutics SA

09/05/23 7:00 AM

NYSE : ADCT

conferences

ADC Therapeutics to Participate in September Investor Conferences

ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in two investor conferences in September. Details of the events are as follows: Morgan Stanley Global Healthcare Conference -

RHEA-AI

positive

08/30/23 7:32 PM

NYSE : ADCT

clinical trial

ADC Therapeutics Announces Updates on ZYNLONTA® LOTIS Clinical Trial Programs at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023)

LOTIS-5: Updated safety run-in results from Phase 3 trial demonstrate 80% ORR, 50% CR rate and median DoR of 8 months with no new safety signals LOTIS-7: Study design of trial evaluating ZYNLONTA ® in patients with r/r non-Hodgkin lymphoma to be highlighted in poster; actively enrolling patients in

RHEA-AI

positive

08/08/23 7:00 AM

NYSE : ADCT

earnings

ADC Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates

2Q 2023 ZYNLONTA ® 1 net sales increased 11% year-over-year; Implemented new go-to-market strategy during the quarter to support growth Operating expenses decreased 20% 2 year-over-year due to portfolio prioritization and organizational efficiencies Pipeline advancing with initial data readouts

RHEA-AI

neutral

08/01/23 7:00 AM

NYSE : ADCT

conferencesearnings

ADC Therapeutics to Host Second Quarter 2023 Financial Results Conference Call on August 8, 2023

ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Tuesday, August 8, 2023 at 8:30 a.m. EDT to report financial results for the second quarter 2023 and provide business updates. To

RHEA-AI

neutral

07/24/23 7:21 AM

NYSE : ADCT

Overland ADCT BioPharma Announces NMPA Accepts Biologics License Application and Grants Priority Review for ZYNLONTA® for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma

Overland ADCT BioPharma, a joint venture of Overland Pharmaceuticals (CY) Inc. and ADC Therapeutics SA (NYSE: ADCT), today announced that the China National Medical Products Administration (NMPA) has accepted

RHEA-AI

very positive

07/20/23 4:05 PM

NYSE : ADCT

clinical trial

ADC Therapeutics Announces Plan to Discontinue the Phase 2 LOTIS-9 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) and Rituximab in Unfit or Frail Previously Untreated DLBCL Patients

ADC Therapeutics SA (NYSE: ADCT) today announced that it plans to discontinue the Phase 2 LOTIS-9 clinical trial evaluating ZYNLONTA ® (loncastuximab tesirine-lpyl) and rituximab (Lonca-R) in unfit or frail patients with previously

RHEA-AI

neutral

07/11/23 7:00 AM

NYSE : ADCT

clinical trial

ADC Therapeutics Announces Voluntary Pause of Enrollment in the Phase 2 LOTIS-9 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) and Rituximab in Unfit or Frail Previously Untreated DLBCL Patients

ADC Therapeutics SA (NYSE: ADCT) today announced a voluntary pause in the enrollment of new patients in the Phase 2 LOTIS-9 clinical trial (ClinicalTrials.gov Identifier: NCT05144009) evaluating ZYNLONTA ® (loncastuximab tesirine-lpyl) and

RHEA-AI

neutral

06/15/23 7:15 AM

NYSE : ADCT

management

ADC Therapeutics Announces Evolution of Board of Directors

ADC Therapeutics SA (NYSE: ADCT) today announced the election of

RHEA-AI

very positive

06/09/23 7:15 AM

NYSE : ADCT

ADC Therapeutics Announces Updated LOTIS-2 Results Demonstrating Durable, Long-Term Responses of ZYNLONTA® in Relapsed/Refractory DLBCL

ADC Therapeutics SA (NYSE: ADCT) today announced updated results from LOTIS-2, the pivotal Phase 2 clinical trial of

RHEA-AI

positive

06/01/23 7:15 AM

NYSE : ADCT

conferences

ADC Therapeutics to Participate in the Jefferies Healthcare Conference

ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference in New York City on Thursday, June 8 th at 8:30 a.m. EDT. A live webcast

RHEA-AI

positive

1 2 3 4 5 6 7 8 9 10 Next